|
Synonyms: GA-101 | GA101 | Gazyva®
obinutuzumab is an approved drug (FDA (2013), EMA (2014))
Compound class:
Antibody
Comment: Obinutuzumab is a third-generation, humanized and glyco-engineered anti-CD20 IgG1 mAb. Prior to 2009 obinutuzumab was known as afutuzumab.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. 
View more information in the IUPHAR Pharmacology Education Project: obinutuzumab |
| Immunopharmacology Disease | |||
| Disease | X-Refs | Comment | References |
| Chronic lymphocytic leukemia |
Disease Ontology:
DOID:1040 OMIM: 151400 Orphanet: ORPHA67038 |
Approved for use in combination with chemotherapy in patients who have received no prior therapy. | |
| Follicular lymphoma |
Disease Ontology:
DOID:0050873 |
Approval is for a combination therapy of obinutuzumab with bendamustine, followed by obinutuzumab monotherapy. | |
